Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441889 · ClinicalTrials.gov registry record · Phase 1
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
A Phase 1 study, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT07441889: Recruiting Phase 1 study, sponsored by University of Virginia.
NCT07441889 is a Phase 1 study that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07441889, a Phase 1 study, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.
Primary Outcome
DLTs in the dose escalation phase
Interventions
- DRUG HER2 FPBMC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-10 |
| Phase | Phase 1 |
What NCT07441889 shows while recruiting
NCT07441889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which HER2 FPBMC is the first listed.
NCT07441889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07441889 about?
NCT07441889 is a clinical study titled "HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)". The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC b...
What is the current status of trial NCT07441889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2026-06. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07441889?
The interventions under investigation include: HER2 FPBMC (DRUG).
Who is sponsoring clinical trial NCT07441889?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07441889's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia